Last days to actively participate in the class action; Portnoy law firm

0

HyreCar, Inc. Investors with losses are encouraged to contact the company before 12 October 2021; Click on here submit business information

Katapult Holdings, Inc. Investors with losses are encouraged to contact the company before October 26, 2021; Click on here submit business information

Cassava Sciences, Inc. Investors with losses are encouraged to contact the company before October 26, 2021; Click on here submit business information

LOS ANGELES, October 04, 2021 (GLOBE NEWSWIRE) – The Portnoy law firm informs investors that a class action lawsuit has been filed on behalf of HyreCar, Inc. (NASDAQ: HYRE) investors who acquired shares between May 14, 2021 and August 20, 2021. Investors have until October 12, 2021 to seek an active role in this litigation.

Investors are encouraged to contact a lawyer Lesley F. Portnoy, to determine eligibility to participate in this action, by phone at 310-692-8883 or E-mail, Where Click here join the case.

It is alleged in this complaint that Hyzon throughout the Class Period made misleading and / or false statements and / or failed to disclose that: (1) Hyzon had misrepresented the nature of his “customer” contracts and severely embellished its “offers” and “partnerships” with customers; (2) Hyzon did not deliver its vehicles announced in 2021, within the announced deadlines; and (3) the defendants’ public statements were materially false and / or misleading at all relevant times, accordingly. The lawsuit claims investors suffered damage when the real details entered the market.

A class action has already been filed. If you wish to act as the principal applicant, you must apply to the Court no later than October 12, 2021.

The Portnoy law firm informs investors that a class action lawsuit has been filed on behalf of Katapult Holdings, Inc. (NASDAQ: KPLT) investors who acquired shares between December 18, 2020 and August 10, 2021. Investors have until October 26, 2021 to seek an active role in this litigation.

Investors are encouraged to contact a lawyer Lesley F. Portnoy, to determine eligibility to participate in this action, by phone at 310-692-8883 or E-mail, Where Click here join the case.

It is alleged in this complaint that Katapult, throughout the Class Period, made misleading and / or false statements and / or failed to disclose that: (1) Katapult’s e-commerce retail sales and consumer spending was on the decline; (2) despite Katapult’s claims that the company was a compelling and clear value proposition for merchants and consumers alike, transforming the way unprivileged consumers buy essential products and allowing merchants to access this evil segment served, Katapult lacked visibility into their consumers’ future shopping behavior; and (3) Katapult’s positive statements about the business, operations and prospects of the Company were materially false and misleading and / or lacked reasonable basis, because of the foregoing. The lawsuit claims that investors suffered damage when the real details entered the market.

A class action has already been filed. If you wish to act as the principal applicant, you must apply to the Court no later than October 26, 2021.

The Portnoy law firm informs investors that a class action lawsuit has been filed on behalf of Cassava Sciences, Inc. (NASDAQ: SAVA) investors who acquired shares between September 14, 2020 and August 27, 2021. Investors have until October 26, 2021 to seek an active role in this litigation.

Investors are encouraged to contact a lawyer Lesley F. Portnoy, to determine eligibility to participate in this action, by phone at 310-692-8883 or E-mail, Where Click here join the case.

The investigation focuses on whether Cassava made misleading and / or false statements and / or failed to disclose information relevant to investors. Cassava has announced supposedly positive results from a clinical trial of simufilam for the treatment of patients with Alzheimer’s disease. On July 30, 2021, despite Cassava’s claims, health industry news site STAT published the concerns of scientists unaffiliated with the study, describing the results as “exaggerated” and “uninterpretable.” A citizen petition was submitted to the FDA on August 18, 2021, calling on the agency to suspend ongoing studies of simufilam until the agency can verify data already submitted by cassava. The petition identifies “suspected errors and anomalies” in the Cassava data “of sufficient frequency and magnitude to strongly suggest scientific misconduct.” On August 25, 2021, Cassava shares fell more than 31%, based on the news.

A class action has already been filed. If you wish to act as the principal applicant, you must apply to the Court no later than October 26, 2021.

Please visit our website to view more information and submit your transaction information.

The Portnoy law firm represents investors in the pursuit of claims arising from corporate wrongdoing. The company’s founding partner has recovered more than $ 5.5 billion for aggrieved investors. Lawyer advertising. Past results do not guarantee similar results.

Lesley F. Portnoy, Esq.
CA and NY bar admitted
[email protected]
310-692-8883
www.portnoylaw.com

Lawyer Advertising


Source link

Leave A Reply

Your email address will not be published.